July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Tolerating Subretinal Fluid in the Treatment of Neovascular Age-Related Macular Degeneration With Ranibizumab Using a Treat and Extend Regimen
Author Affiliations & Notes
  • Jennifer Arnold
    Marsden Eye Specialists, Sydney, New South Wales, Australia
  • Caroline Markey
    Markey Medical Consulting, Sydney, New South Wales, Australia
  • Ian McAllister
    Centre for Ophthalmology and Visual Science, Lions Eye Institute, The University of Western Australia, Perth, Western Australia, Australia
  • Mark C Gillies
    Macular Research Group, Save Sight Institute, The University of Sydney, Sydney Eye Hospital, Sydney, New South Wales, Australia
  • Alex Hunyor
    Retina Associates, Chatswood; Save Sight Institute, The University of Sydney, Sydney Eye Hospital, Sydney, New South Wales, Australia
  • Robyn H Guymer
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital and Ophthalmology, University of Melbourne, Melbourne, Victoria, Australia
  • Footnotes
    Commercial Relationships   Jennifer Arnold, Allergan (C), Allergan (R), Bayer (R), Bayer (C), Novartis (C), Novartis (R); Caroline Markey, Novartis (C); Ian McAllister, Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R); Mark Gillies, Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R), Ophthea (C), Roche (C); Alex Hunyor, Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R); Robyn Guymer, Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R)
  • Footnotes
    Support  Sponsor: Novartis Pharmaceuticals Australia
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1461. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jennifer Arnold, Caroline Markey, Ian McAllister, Mark C Gillies, Alex Hunyor, Robyn H Guymer; Tolerating Subretinal Fluid in the Treatment of Neovascular Age-Related Macular Degeneration With Ranibizumab Using a Treat and Extend Regimen. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1461.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : It is unknown whether subretinal fluid (SRF) presence can be tolerated when treating patients with anti-VEGF therapy without compromising visual outcomes. The FLUID study was a 24 month, phase IV, single masked, multicentre, randomized clinical trial of eyes with neovascular age-related macular degeneration (nAMD) treated with ranibizumab. We tested the hypothesis that tolerating SRF can achieve similar visual acuity outcomes using a treat and extend (T&E) regimen relative to SRF not being tolerated.

Methods : We randomized subjects with active CNV affecting the fovea to receive monthly 0.5 mg ranibizumab until complete resolution of SRF and intraretinal fluid (IRF) (intensive arm i.e. SRF intolerant) or resolution of IRF and >200 µm SRF (relaxed arm i.e. SRF tolerant) before extending intervals. A 5 letter non-inferiority margin was applied to the primary outcome of mean change in BCVA from Baseline to Month 24.

Results : Of the 349 subjects randomised (174 in intensive group, 175 in relaxed group), 279 (79.9%) completed the Month 24 study. Baseline characteristics were well-balanced with the exception of area of lesion (p<0.05) and area of CNV (p<0.01) both of which were larger in the intensive group. The mean (SD) change in BCVA from Baseline to Month 24 was 3.2 (16.51) letters in the intensive group and 2.5 (16.56) letters in the relaxed group demonstrating non-inferiority of the relaxed treatment to the intensive treatment (p=0.787). There was no difference between the intensive and relaxed groups for the proportion of subjects with ≥20/40 VA (55.1% and 58.3%, respectively; p=0.901) nor ≤20/200 VA (8.2% and 8.6%, respectively; p=0.397). The average reduction in central retinal thickness was larger numerically in the intensive group compared to the relaxed group (p=0.054). Numerically, more subjects in the relaxed group never resolved their baseline SRF (15%) nor their baseline IRF (14.8%) compared to the intensive group (9.5%; p=0.249 and 7.5%; p=0.059, respectively). Subjects in the relaxed group received fewer ranibizumab injections over the 24-month study (mean [SD]; 15.8 [5.91]) than those in the intensive group (17 [6.48]; p=0.001).

Conclusions : Patients treated with a ranibizumab T&E protocol that tolerates <200 µm SRF may achieve visual acuity that is comparable to that achieved when treatment aims to completely resolve all SRF.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×